|Bid||117.45 x 800|
|Ask||117.60 x 1800|
|Day's Range||116.01 - 120.07|
|52 Week Range||83.00 - 195.97|
|Beta (3Y Monthly)||3.37|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 30, 2018 - Aug 3, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||204.73|
CNBC's Meg Tirrell reports on the FDA set to review two new depression drugs and what it could mean for the pharma companies behind the drugs.
State regulators are investigating whether the utilities company's facilities were involved in the beginning of the California wildfires that have killed 31 people. The drop came after Leerink, an investment bank focused on health care, described the company as its least favorite in the biopharmaceutical space, giving the stock a price target of $80 -- well below Monday's closing price of $121.44. Leerink said Sage's drug for postpartum depression, Zulresso, is a niche product that will have low peak sales and a slow ramp after approval.
Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the Company will present at the Stifel 2018 Healthcare Conference on Wednesday, November 14, 2018 at 09:30 A.M.
FDA Advisory Committee Meeting outcome supports approval of ZULRESSO™ injection as the first medicine specifically indicated for the treatment of postpartum depressio
NEW YORK, NY / ACCESSWIRE / November 5, 2018 / AcelRx Pharmaceuticals saw big gains this past Friday after announcing third quarter results and an update on DSUVIA receiving FDA approval. Shares of Sage Therapeutics were halted after its treatment Zulresso, was recommended by an FDA approval for postpartum depression. AcelRx Pharmaceuticals, Inc. shares closed up 15.66% on about 20 million shares traded on Friday.
Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on November 1, 2018, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 15,400 shares of its common stock to 12 new employees under Sage’s 2016 Inducement Equity Plan. The 2016 Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Sage (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Sage, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
An advisory panel to the U.S. Food and Drug Administration on Friday recommended Sage Therapeutics Inc's experimental treatment for postpartum depression, saying the benefits of the drug outweighed risks. The panel voted 17-1 in favor of the injectable treatment, Zulresso, which aims to treat major episodes of depression during pregnancy or within four weeks of delivery. "I believe that (Zulresso) may be a game changer in the treatment of postpartum depression.
Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) and Drug Safety and Risk Management Advisory Committee (DSaRM) jointly voted (17 yes, 1 no) that data support the favorable benefit-risk profile of ZULRESSO™ (brexanolone) injection for the treatment of postpartum depression (PPD) when administered by qualified staff in a facility that has been certified under a Risk Evaluation and Mitigation Strategies (REMS) program. “We are pleased the FDA Advisory Committee agreed that the benefit/risk profile of ZULRESSO supports this novel approach to treating PPD, reflecting the need for an innovative treatment option that may rapidly alleviate suffering for women with PPD and their families,” said Jeff Jonas, M.D., chief executive officer of Sage.
The first-ever drug to treat postpartum depression, developed by Cambridge-based Sage Therapeutics Inc., appears set for likely approval by the FDA after favorable votes on three key questions by members of an advisory committee Friday. The 18 members of the FDA's Psychopharmacologic Drugs Advisory Committee voted unanimously to say the trial data on the drug by Sage (Nasdaq: SAGE), which would be sold as Zulresso, provided "substantial evidence ... to support a claim of effectiveness... for the treatment of postpartum depression." In the second vote, 16 members said the company "adequately characterized the safety profile" of the drug, with two members abstaining. The third vote, 17 members voted yes and one voted no on the question, "do the benefits outweigh the risks of brexanolone for the treatment of postpartum depression?" The FDA has until Dec. 19 to decide whether or not to approve the drug for sale in the U.S. Although the regulator doesn't have to follow the recommendations of its advisory committees, it usually does.
Sage Therapeutics Inc. said Friday its stock has been halted premarket ahead of a joint meeting of the U.S. Food and Drug Administration Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee to discuss its Zulresso treatment for postpartum depression. The meeting is scheduled for 8.00 a.m. Eastern to 5.00 p.m. Shares have fallen 16.5% in 2018, while the S&P 500 has gained 2.5%.
Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that NASDAQ has halted trading of the company’s common stock.
NEW YORK, NY / ACCESSWIRE / October 31, 2018 / U.S. markets rebounded on Tuesday as trade tensions eased after President Trump hinted that the U.S. was prepared to negotiate a trade deal with China. During ...
was mentioned in the fast paced "Lightning Round" on Jim Cramer's "Mad Money" program Thursday night. In this daily bar chart of SAGE, below, we can see that prices drifted sideways from February to the end of August but after that prices broke support and started a better defined downtrend. SAGE is also below the 200-day moving average line whose slope turned negative in late September.
It's that time again! "Mad Money" host Jim Cramer rang the lightning round bell, which means he gave his take on callers' favorite stocks at rapid speed. Mazor Robotics Ltd. MZOR-IL : " It's being bought , so it's kind of done. Take-Two Interactive Software TTWO : "OK, Take-Two Interactive got some incredible reviews for 'Red Dead Redemption .' The stock's up big.
On October 24, Alkermes (ALKS) stock closed at $40.03, which is 44% below its 52-week high of $71.22 on February 16. On October 23, the stock closed at $40.19, which is a ~3.42% rise from its prior day’s close of $38.86. Also on October 23, Alkermes hit its 52-week low of $37.01. In September, Alkermes announced that it has initiated an expansion of its ongoing Phase 1 trial.
NEW YORK, NY / ACCESSWIRE / October 24, 2018 / U.S. stocks finished in the red on Tuesday, with the S&P 500 falling for the 5th consecutive session, as a drop in Asian markets continued to raise global ...
Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, November 6, 2018 at 8:00 A.M.
NEW YORK, Oct. 19, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Insys Therapeutics (INSY) is a specialty pharmaceuticals company focused on developing cannabinoids and sprays. It reported EPS of -$0.37 on revenues of $23.47 million in the second quarter of 2018.
As discussed earlier, Sage Therapeutics’ (SAGE) portfolio includes products under development for the treatment of life-threatening central nervous system (or CNS) disorders through two different programs: GABA receptor systems and NMDA receptor systems.
As discussed earlier, Sage Therapeutics (SAGE) is focused on the development of products for the treatment of life-threatening central nervous system (or CNS) disorders. The products under development include SAGE-718 and SAGE-904.
Sage Therapeutics’ (SAGE) product portfolio includes products under development for the treatment of various rare and life-threatening central nervous system disorders.
Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company, is developing medicines for the treatment of life-altering central nervous system disorders like major depressive disorder, Parkinson’s disease, postpartum depression, and others.